Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Ondansetron). Same strength and form. Confirm the switch with your doctor or pharmacist.
More from Periset
Other strengths and forms by The ACME Laboratories Ltd.
Indications & Uses
Periset is indicated for:
Pharmacology
Ondansetron is a potent, highly selective 5HT3 receptor antagonist. Its precise mode of action in controlling nausea and vomiting is not known. Chemotherapy drugs and radiotherapy can trigger the release of 5HT in the small intestine, which starts a vomiting reflex by activating vagal afferents through 5HT3 receptors; ondansetron blocks this reflex from starting. Activation of vagal afferents may also release 5HT in the area postrema, a region on the floor of the fourth ventricle, which can further promote vomiting through a central mechanism. Ondansetron's effect in managing nausea and vomiting caused by cytotoxic chemotherapy and radiotherapy is therefore thought to result from its blocking of 5HT3 receptors on neurons in both the peripheral and central nervous systems. How it works in post operative nausea and vomiting is not known, though it may share common pathways with chemotherapy induced nausea and vomiting.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Chemotherapy-induced nausea and vomiting, adults and pediatric patients (6 months to 18 years):
8 mg tablet or orodispersible tablet: three doses of 0.15 mg/kg, up to a maximum of 16 mg per dose.
4 mg orodispersible tablet: three doses of 0.15 mg/kg, up to a maximum of 16 mg per dose.
three doses of 0.15 mg/kg, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Radiotherapy-induced nausea and vomiting, adults:
8 mg tablet or orodispersible tablet: the first dose is 8 mg by mouth 1 to 2 hours before radiotherapy. After radiotherapy, give 8 mg by mouth every 8 hours for up to 5 days after a course of treatment.
4 mg orodispersible tablet: three doses of 0.15 mg/kg, up to a maximum of 16 mg per dose.
three doses of 0.15 mg/kg, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Postoperative nausea and vomiting, adults:
8 mg tablet or orodispersible tablet: 16 mg, given as two 8 mg tablets.
4 mg orodispersible tablet: 16 mg.
4 mg.
Pediatrics (over 40 kg), injection: 4 mg.
Pediatrics (40 kg), injection: 0.1 mg/kg.
Chemotherapy-induced nausea and vomiting, adults, geriatric patients and children of 12 years or over (oral solution):
For highly emetogenic cancer chemotherapy, give 30 ml (24 mg) of Ondansetron Oral Solution 30 minutes before the chemotherapy starts.
For moderately emetogenic cancer chemotherapy, give 10 ml (8 mg) of Ondansetron Oral Solution 30 minutes before the chemotherapy starts. A further 10 ml dose should be given 8 hours after the first dose. Then give one 10 ml dose twice a day (every 12 hours) for 1 to 2 days after the chemotherapy is finished.
Pediatric patients (4 to 11 years): 5 ml (4 mg) of Ondansetron Oral Solution should be taken 30 minutes before chemotherapy starts. The other 2 doses should be taken 4 and 8 hours after the first dose. After that, give 5 ml of the oral solution 3 times a day (every 8 hours) for 1 to 2 days after the chemotherapy is finished.
Radiotherapy-induced nausea and vomiting, oral solution (adults, geriatric patients and children of 12 years or over):
The recommended oral dose is 10 ml (8 mg) of Ondansetron Oral Solution 3 times daily.
For total body irradiation, give 10 ml (8 mg) of Ondansetron Oral Solution 1 to 2 hours before each fraction of radiotherapy given each day.
For single high-dose fraction radiotherapy to the abdomen, give one 10 ml dose of Ondansetron Oral Solution 1 to 2 hours before radiotherapy. Later doses follow every 8 hours after the first dose, for 1 to 2 days after radiotherapy is completed.
For daily fractionated radiotherapy to the abdomen, give 10 ml (8 mg) of Ondansetron Oral Solution 1 to 2 hours before radiotherapy. Later doses follow every 8 hours after the first dose, for each day radiotherapy is given.
Postoperative nausea and vomiting, oral solution (adults, geriatric patients and children of 12 years or over):
Give 20 ml (16 mg) of Ondansetron Oral Solution 1 hour before induction of anesthesia.
Oral soluble film:
To prevent nausea and vomiting with highly emetogenic cancer chemotherapy, the adult oral dose is 24 mg, given one after another as three 8 mg films, 30 minutes before chemotherapy starts.
To prevent nausea and vomiting with moderately emetogenic cancer chemotherapy:
Adults and pediatric patients 12 years of age and older take one 8 mg film 30 minutes before chemotherapy, followed by an 8 mg dose 8 hours later. Then give one 8 mg film twice a day (every 12 hours) for 1 to 2 days after the chemotherapy is finished.
Pediatric patients 4 through 11 years of age take one 4 mg film three times a day. The first dose goes 30 minutes before chemotherapy, with later doses 4 and 8 hours after that. Then give one 4 mg film three times a day (every 8 hours) for 1 to 2 days after the chemotherapy is finished.
To prevent nausea and vomiting with radiotherapy, the adult dose is one 8 mg film three times a day.
Postoperative nausea and vomiting: the adult dose is 16 mg, given one after another as two 8 mg films, 1 hour before anesthesia.
Side Effects
Frequently reported adverse events were headache, constipation and diarrhea, though most were mild or moderate in nature. In chemotherapy induced nausea and vomiting, rash occurred in approximately 1% of patients receiving Vomisal. There have also been reports of a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. Rare cases of anaphylaxis, bronchospasm, tachycardia, angina (chest pain), hypokalemia and shortness of breath have also been reported; apart from bronchospasm and anaphylaxis, their relationship to Vomisal is unclear. There is no evidence of extrapyramidal reactions, though in rare cases oculogyric crisis has appeared alone, as well as with other dystonic reactions, without definitive clinical evidence. In PONV, with the exception of headache, rates of these events were not significantly different between the Vomisal and placebo groups.
Cautions & Contraindications
Warnings & Precautions
Hypersensitivity reactions have occurred in patients who were also hypersensitive to other selective 5-HT3 receptor antagonists. Vomisal does not stimulate gastric or intestinal motility, so it should not be used as a substitute for nasogastric suction. In patients recovering from abdominal surgery, or in those receiving chemotherapy who develop nausea and vomiting, Vomisal may mask an underlying progressive ileus or gastric distension.
Contraindications
Ondansetron should not be used by anyone who is hypersensitive to it or to any of its ingredients. It must also not be taken together with apomorphine.
Pregnancy & Breastfeeding
Ondansetron did not cause cancer in 2-year studies in rats and mice, using oral doses as high as 10 and 30 mg/kg per day respectively, and it showed no mutagenic effect in standard genetic toxicity tests. Oral doses up to 15 mg/kg per day did not affect fertility or overall reproductive performance in male and female rats.
Reproduction studies in pregnant rats and rabbits, using daily oral doses of up to 15 and 30 mg/kg per day respectively, found no evidence that Ondansetron impaired fertility or harmed the developing fetus. However, no adequate, well-controlled studies have been conducted in pregnant women. Ondansetron does pass into the breast milk of rats, so it should be used with caution in nursing mothers.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Impaired renal function: The dose is the same as for the general population.
Impaired hepatic function: In patients with severe hepatic impairment, a single maximal daily dose of 8 mg is recommended. It should be infused over 15 minutes, starting 30 minutes before the emetogenic chemotherapy begins.
Children aged 4 years or younger: There is little information on dosage for paediatric patients in this age group.
Over 65 years: No dosage adjustment is needed for patients over the age of 65.
Storage
Keep Ondansetron in a dry place at a temperature not above 30ºC. Protect it from light and moisture.
Drug Interactions
Common questions about Periset 16 mg
What is Periset 16 mg Suppository?
Periset 16 mg Suppository is a medicine that contains Ondansetron. It is made by The ACME Laboratories Ltd. It belongs to the Anti-emetic drugs group of medicines.
What is Periset used for?
Periset is used for: Nausea and Vomiting, Cancer.
What are the side effects of Periset?
Frequently reported adverse events were headache, constipation and diarrhea, though most were mild or moderate in nature. In chemotherapy induced nausea and vomiting, rash occurred in approximately 1% of patients receiving Vomisal.
Can I take Periset during pregnancy or while breastfeeding?
Ondansetron did not cause cancer in 2-year studies in rats and mice, using oral doses as high as 10 and 30 mg/kg per day respectively, and it showed no mutagenic effect in standard genetic toxicity tests. Oral doses up to 15 mg/kg per day did not affect fertility or overall reproductive performance in male and female rats. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Periset?
Keep Ondansetron in a dry place at a temperature not above 30ºC. Protect it from light and moisture.
Can I take other medicines with Periset?
Some medicines can interact with Ondansetron, for example: Guaifenesin + Dextromethorphan + Menthol. Tell your doctor or pharmacist about every medicine you take.
Do I need a prescription for Periset?
Periset is a prescription (Rx) medicine. Take it as your doctor advises.